ANIKA

Your life. *In motion.*

The Viscosupplement Family

Joint Relief for All Your Patients

The Viscosupplement Family Brochure | Product information

For all your patients

Anika offers a family of viscosupplements to manage pain for all your patients - from acute sports injuries to degenerative osteoarthritis (OA)

THE ANIKA REPUTATION

- Natural non-animal sourced ultra-pure hyaluronan from bacterial fermentation
- Trusted brand for nearly 30 years
- Excellent safety profile, with over 35 million treatments worldwide
- Strong efficacy profile for a portfolio of products providing rapid and long-term relief from the pain of OA
- Convenient non-surgical treatment that avoids oral medication side-effects and may delay the need for total knee replacement (TKR) up to 3.6 years[1]

Continuum of care



Information applies exclusively to territories outside of USA.

The effects of OA on synovial fluid

Osteoarthritis reduces the concentration and molecular weight of the natural hyaluronic acid (HA) found in the synovial fluid, resulting in pain and stiffness, reduced function and impacting quality of life.

- Reduced ability to absorb shock
- Decreased lubrication leading to stiffness
- Moderate to severe joint pain and damage

Supplementing the naturally occurring hyaluronan in the synovial joint space helps mimic the flow of normal synovial fluid and restore homeostasis of the joint.[1]

HA injections may delay total knee replacements by 3.6 years.[1]



1. Altman, R., et. al. Hyaluronic Acid Injections Are Associated with Delay of Total Knee Replacement Surgery in Patients with Knee Osteoarthritis: Evidence from a Large U.S. Health Claims Database. 2015 Dec; doi 10.1371/journal.pone.0145776.

Information applies exclusively to territories outside of the USA

The science behind our solutions

Naturally sourced hyaluronic acid (HA) forms the foundation for our proprietary purification and formulation processes. We produce high quality therapeutics designed to replace the natural HA lost from synovial fluid in arthritic knee joints.

THE BENEFITS OF ANIKA'S UNIQUE APPROACH:

- Preserves the natural integrity of the HA molecule
- Provides a natural path to relieve pain and restore function, thereby avoiding potential side-effects of medication and delaying surgery
- Optimal molecular weight averaging 1.9 million Daltons[2]

+ THE CROSSLINKING ADVANTAGE

Our proprietary crosslinking process creates molecular stability and enables heat sterilization to promote HA longevity.

2. American Academy of Orthopaedic Surgeons. Academy A, AAOS. Treatment of osteoarthritis of the knee—evidence-based guidelines. Am Acad Orthop Surg Board Dir 2013;973;. Doi: 10.5435/JAAOS-21-09-571.

Fast acting. Long lasting.

Cingal® is a powerful, first-in-class treatment that combines the benefit of Anika's proprietary high concentration cross-linked hyaluronic acid (HA) formulation, approved for long-term pain relief of the symptoms of OA, with a well-established FDA-approved corticosteroid to treat inflammation and provide additional short-term pain relief.

THE CINGAL ADVANTAGE

- First and only approved HA plus corticosteroid combination viscosupplement*
- Provides fast-acting pain relief within days of injection[3]
- Long lasting pain relief up to six months[3]
- Strong safety profile in both an initial injection and repeat injection[4]
- High delivered dose of cross-linked hyaluronic acid (88mg) plus 18mg triamcinolone hexacetonide (TH) in a convenient single injection treatment
- Highly concentrated, non-animal based HA
- CE Mark approved for use in the knee



Cingal study data demonstrated statistically significant rapid and long-term pain relief, delivering a **72% improvement** in WOMAC pain at 26 weeks relative to baseline[3]

Saline
HA alone
CINGAL

* CINGAL is CE Mark approved and Health Canada approved

3. Hangody L, et al. Intraarticular Injection of a Cross-Linked Sodium Hyaluronate Combined with Triamcinolone Hexacetonide (Cingal) to Provide Symptomatic Relief of Osteoarthritis of the Knee. Cartilage 2017 May; doi: 10.1177/1947603517703732.
4. CINGAL 13-02, an open-label follow-on study to Cingal 13-01

Information applies exclusively to territories outside of USA.

MONOVISC®

One injection. One treatment.

Monovisc® is a single injection, high-dose viscosupplement approved for the treatment of osteoarthritis (OA) in the knee. Monovisc lubricates the knee joint and delivers fast pain relief that can last up to six months.[5,7]

THE MONOVISC ADVANTAGE

- Single injection treatment
- Highest delivered dose of hyaluronic acid (88mg) in any 100% HA single injection treatment
- Approved to deliver strong, long-lasting pain relief for up to 26 weeks[5]
- Safely used for over 10 years in nearly 2 million injections worldwide[6]
- Highly concentrated, high molecular weight, non-animal sourced HA

THE MONOVISC PATIENT

- Younger people with sports related injuries
- People who prefer a single visit treatment
- Athletes needing viscoelastic supplement for joint lubrication and mechanical support
- People who demand quick recovery

TOTAL DELIVERED DOSE OF HYALURONIC ACID (HA)[10]



5. Monovisc 0702 Pivotal Clinical Trial. FDA Monovisc Summary of Safety and Effectiveness Data 2014.
6. Anika data on file.

ORTHOVISC®

The Trusted Brand

Orthovisc® is an ultra pure, high molecular weight injectable HA viscosupplement that helps restore viscosity and elasticity to the synovial fluid within osteoarthritic joints. Orthovisc is a three injection treatment delivering HA with viscoelastic properties similar to healthy synovial fluid[7] with up to 6 months of pain and symptom relief.

+ THE ORTHOVISC ADVANTAGE

- Used for nearly 25 years
- Natural non-animal sourced HA
- 3-4 injection regimen[8]
- High concentration HA for relief of pain that lasts through 6 months[7]
- No confirmed pseudoseptic reactions in over 15 million injections worldwide[6]
- Can extend the need for total knee replacement (TKR) up to 3.6 years[1]

THE ORTHOVISC PATIENT

- Wants to remain active
- Diagnosed with mild to moderate degenerative osteoarthritis
- People who prefer a series of treatments for financial or other reasons
- Patients whose physicians recommend more frequent monitoring

7. Brandt KD, Block JA, Michalski JP, Moreland LW, Caldwell JR, Lavin PT. Efficacy and safety of intra-articular sodium hyaluronate in knee osteoarthritis. ORTHOVISC Study Group. Clin Orthop Relat Res 2001;(385):130 - 43.
8. FDA Monovisc Summary of Safety and Efficacy Data (SSED). Application Number: P090031.

Information applies exclusively to territories outside of USA.

Cingal

PRODUCT INFORMATION

- CE Mark approved
- Single injection regimen
- 4mL - provides 22 mg/ml HA and 4.5 mg/ml triamcinolone hexacetonide
- 36 month shelf life
- Store at 2 to 25°C
- Total HA concentration of 88 mg
- Molecular Weight: >1.5m Daltons
- Source: bacterial fermentation
- High molecular weight cross-linked hyaluronic acid (MONOVISC®) combined with triamcinolone hexacetonide

Monovisc

PRODUCT INFORMATION

- FDA approved and CE Mark approved
- Single injection regimen
- 4mL – provides 22 mg/ml HA
- 36 month shelf life
- Store at 2 to 25°C
- Total HA concentration of 88 mg
- Molecular Weight: >1.5m Daltons
- Source: bacterial fermentation
- Cross-linked high-molecular weight HA with proprietary crosslinker
- Low rate of adverse events; similar to ORTHOVISC®

Orthovisc

PRODUCT INFORMATION

- FDA approved and CE Mark approved
- 3-4 injection regimen
- 2mL – provides 15 mg/ml HA
- 24 month shelf life
- Store at 2 to 25°C
- Molecular Weight: >1.5m Daltons
- Total HA concentration of 30 mg
- Source: bacterial fermentation

Refer to the Instructions for Use for complete product information

ANIKA

Anika Therapeutics, Inc.
32 Wiggins Ave, Bedford, MA, USA
www.anikatherapeutics.com

Anika is a global, integrated joint preservation company that leverages proprietary regenerative and restoration therapies to help people feel better faster and remain active. For nearly 30 years and 35 million procedures worldwide, Anika has been passionately advancing quality patient care by enabling people to continue doing what they love.

©2020 Anika Therapeutics, Inc. | 08/20 | AML 900-054/E
Anika, Orthovisc, Monovisc and Cingal are registered trademarks of Anika Therapeutics, Inc.
The information contained in this document applies exclusively to territories outside of the USA

ANIKA